calotatug ginistinag (XMT-2056)

News alerts, weekly reports and conference planners

Company:

GSK, Mersana

Drug class:

HER2-targeted antibody-drug conjugate, STING agonist

HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D

Associations
(2)